

Stefanie Jilg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8030827/publications.pdf>

Version: 2024-02-01

9
papers

324
citations

1477746

6
h-index

1473754

9
g-index

9
all docs

9
docs citations

9
times ranked

704
citing authors

#	ARTICLE	IF	CITATIONS
1	RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. <i>Cancer Cell</i> , 2016, 30, 75-91.	7.7	144
2	Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. <i>Nature</i> , 2020, 588, 157-163.	13.7	90
3	Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. <i>Experimental Hematology and Oncology</i> , 2019, 8, 9.	2.0	36
4	Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST). <i>International Journal of Cancer</i> , 2019, 145, 2292-2303.	2.3	21
5	Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile. <i>Oncotarget</i> , 2018, 9, 17270-17281.	0.8	18
6	Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study. <i>Leukemia and Lymphoma</i> , 2015, 56, 3227-3229.	0.6	6
7	Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis. <i>European Journal of Haematology</i> , 2020, 104, 125-137.	1.1	5
8	Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103197.	0.5	2
9	Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 148, 331.	1.2	2